Melanoma, a highly aggressive and treatment-resistantform of skincancer, remains a significant clinical challenge due to its propensityfor metastasis and poor prognosis. BRD4is a key epigenetic reader that drives oncogenesis by mediating PPIswith acetylated histones and transcription factors (for example, NF-κBand c-MYC), thereby regulating transcriptional elongation and cancercell plasticity. Targeting BRD4’sPPIs offers a promising therapeutic strategy, but conventional fluorescence-basedscreening methods are hindered by autofluorescence interference andfalse positives. The gene discussed is BRD4; the disease is melanoma.